NEW YORK (GenomeWeb) – OmniSeq said today that Hitachi High-Technologies has taken an option to exclusively license its OmniSeq Comprehensive and Immune Report Card tests for clinical distribution in Japan after participating in the company's Series B funding round.

OmniSeq — a subsidiary of the Roswell Park Comprehensive Cancer Center — said it plans to use the funds from the Series B to conduct ongoing retrospective and prospective clinical trials and to generate evidence of the clinical utility of its comprehensive genomic and immune profiling services. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Apr
09
Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies.